Now, it’s worth noting Stock Advisor’s total average return is 1,062% — a market-crushing outperformance compared to 194 % ...

Most patients with chronic rhinosinusitis with nasal polyps no longer used oral corticosteroids after using dupilumab, ...

May 23, 2025 -- The FDA has approved the asthma drug Nucala for adults with chronic obstructive pulmonary disease (COPD). It is the second biologic therapy approved for the condition, following the ...

Skin prick tests and blood tests can diagnose a dust mite allergy. There are also at-home test kits that measure dust mite levels in your home. Leaving food and dirty dishes out overnight can attract ...

Sanofi’s stock narrative is shifting as analysts revise their consensus price target slightly downward, from $106.90 to $106.85. This minor adjustment reflects a careful reassessment of Sanofi’s ...

Delgocitinib has emerged as a promising treatment for CHE, addressing unmet needs and enhancing understanding of this complex condition, notes Raj Chovatiya, MD, PhD, MSCI.

For the primary endpoint, Eczema Area and Severity Index (EASI) improved by 53-61% in a dose-dependent manner across the ...

COVID-19 mRNA vaccination is associated with a reduced incidence of multiple infections and allergic complications.

Sanofi and Regeneron’s Dupixent (dupilumab) could be set for its ninth US approval after the drug met all the primary and ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...

In patients with moderate-to-severe allergic asthma, tezepelumab yields the greatest reduction in exacerbations among ...

Sanofi & Regeneron’s Dupixent pivotal study meets all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis: Paris Monday, November 10, ...